Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: A systematic review and meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 2, 2017, Pages 365-371

  Boerma, R S ^a,b   Sigaloff, K C E ^a,c   Akanmu, A S ^d   Inzaule, S ^a   van Hensbroek, M Boele ^b   de Wit, T F Rinke ^a   Calis, J C ^b  

^a AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^b EMMA CHILDREN S HOSPITAL   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF LAGOS   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

AFRICA SOUTH OF THE SAHARA; ANTIRETROVIRAL THERAPY; ARTICLE; CHILD; CHILDHOOD DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREVALENCE; SYSTEMATIC REVIEW; VIRUS TRANSMISSION; ANTIVIRAL RESISTANCE; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; INFANT; ISOLATION AND PURIFICATION; META ANALYSIS; NEWBORN; PRESCHOOL CHILD; VIROLOGY;

AFRICA SOUTH OF THE SAHARA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; PREVALENCE;

EID: 85014548823     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw463     Document Type: Article

References (31)

1. WHO. Global Health Sector Response to HIV, 2000-2015: Focus on Innovations in Africa-Progress Report. 2015. http://www.who.int/hiv/pub/pro gressreports/2015-progress-report/en/.
2. Gupta RK, Jordan MR, Sultan BJ et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380: 1250-8.
3. Hamers RL, Wallis CL, Kityo C et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-SaharanAfrica after rollout of antiretroviral therapy: amulticentre observational study. Lancet Infect Dis 2011; 11: 750-9.
4. Hamers RL, Schuurman R, SigaloffKCE et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 2012; 12: 307-17.
5. Wittkop L, Günthard HF, de Wolf F et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11: 363-71.
6. Bertagnolio S, Penazzato M, Jordan MR et al. World Health Organization generic protocol to assess drug-resistant HIV among children<18 months of age and newly diagnosed with HIV in resource-limited countries. Clin Infect Dis 2012; 54 Suppl 4: S254-60.
7. Kuhn L, Hunt G, Technau K-G et al. Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. AIDS 2014; 28: 1673-8.
8. Rhee S-Y, Blanco JL, Jordan MR et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient-and sequence-level meta-analysis. PLoS Med 2015; 12: e1001810.
9. ChungMH, Silverman R, Beck IA et al. Increasing HIV-1 pre-treatment drug resistance among antiretroviral-naïve adults initiating treatment between 2006. and 2014 in Nairobi, Kenya. AIDS 2016; 30: 1680-2.
10. UNAIDS. 2014 Progress Report on the Global Plan Towards the Elimination of HIV Infections Among Children by 2015 and Keeping their Mothers Alive. 2014. http://www.unaids.org/sites/default/files/documents/JC2681_2014-Global-Plan-progress_en.pdf.
11. Paredes R, Marconi VC, Lockman S et al. Impact of antiretroviral drugs in pregnant women and their children in Africa: HIV resistance and treatment outcomes. J InfectDis 2013; 207 Suppl 2: S93-100.
12. Liberati A, Altman DG, TetzlaffJ et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6: e1000100.
13. United Nations Statistics Division. Composition of Macro Geographical (Continental) Regions, Geographical Sub-Regions, and Selected Economic and Other Groupings. http://millenniumindicators.un.org/unsd/methods/m49/m49regin.htm.
14. WHO. WHO HIV Drug Resistance Report 2012. 2012. http://www.who.int/hiv/pub/drugresistance/report2012/en/.
15. Rojas Sánchez P, Holguín A. Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review. J Antimicrob Chemother 2014; 69: 2032-42.
16. Towler WI, Barlow-Mosha L, Church JD et al. Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. AIDS Res HumRetroviruses 2010; 26: 563-8.
17. Fokam J, Salpini R, Santoro MM et al. Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. Pediatr Infect Dis J 2011; 30: 1062-8.
18. Zeh C, Weidle PJ, Nafisa L et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention ofmother-to-child transmission: a secondary analysis. PLoSMed 2011; 8: 1-10.
19. Inzaule SC, Weidle PJ, Yang C et al. Prevalence and dynamics of the K65R drug resistance mutation in HIV-1-infected infants exposed to maternal therapy with lamivudine, zidovudine and either nevirapine or nelfinavir in breast milk. JAntimicrobChemother 2016; 71: 1619-26.
20. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2013. http://who.int/hiv/pub/guidelines/arv2013/download/en/.
21. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach-Second Edition. 2016. http://www.who.int/hiv/pub/arv/arv-2016/en/.
22. Kityo C, Boerma RS, SigaloffKC et al. Transmitted drug resistance and first-line ART treatment outcomes in Ugandan children. In: Abstracts of the Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2016. Abstract 849. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
23. ClintonHealthAccess Initiative. 2014 Antiretroviral (ARV) Ceiling Price List. 2014. http://45.55.138.94/content/uploads/2015/05/CHAI-ARV-Ceiling-Price-2014-Final_English.pdf.
24. Médecins Sans Frontièrs. Untangling the Web of Antiretroviral Price Reductions. 2014. http://www.msfaccess.org/content/untangling-web-anti retroviral-price-reductions-17th-edition-%E2%80%-93july-2014.
25. Cipla. Cipla Announces US FDA Approval for the World's First Paediatric Lopinavir and Ritonavir Oral Pellets for the Treatment of AIDS in Infants and Young Children. Press release 2015. http://www.cipla.com/uploads/mediakit/1443620979_Press-Release-Cipla-announces-US-FDA-approval-for-LPV-r.pdf.
26. Musiime V, Fillekes Q, Kekitiinwa A et al. The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in African HIV-infected children. J Acquir ImmuneDefic Syndr 2014; 66: 148-54.
27. HuntGM, CoovadiaA, Abrams EJ et al. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS 2011; 25: 1461-9.
28. Violari A, Lindsey JC, HughesMD et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. NEngl JMed2012; 366: 2380-9.
29. Ruel TD, Kakuru A, Ikilezi G et al. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir-ritonavir or nonnucleoside-reverse-transcriptase-inhibitor therapy. J Acquir Immune Defic Syndr 2014; 65: 535-41.
30. The PENPACT-1 (PENTA 9/PACTG 390) Study Team. First-line antiretroviral therapywith a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis 2011; 11: 273-83.
31. Rhee S-Y, Jordan MR, Raizes E et al. HIV-1 drug resistancemutations: potential applications for point-of-care genotypic resistance testing. PLoS One 2015; 10: e0145772.